Dialysis News and Research

Latest Dialysis News and Research

Japan's MHLW grants full marketing authorization to REVLIMID

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.

25 Jun 2010

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.

25 Jun 2010

GI symptoms in peritoneal dialysis patients correlated with chronic renal failure

Gastrointestinal (GI ) symptoms are proven to be more common in patients undergoing peritoneal dialysis than in patients with chronic renal failure having hemodialysis. However, whether the onset of these GI symptoms is related to the chronic renal failure itself, its treatment, or alternatively, other factors, is still unknown

25 Jun 2010

Digoxin drug may increase risk of premature death in patients with kidney disease

For patients with kidney disease on dialysis, the widely used heart medication digoxin may lead to an increased risk of premature death, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

25 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Risk, incidence of VTE differs between races

A new study of 1,960 White-Americans and 368 Black-Americans with objectively diagnosed venous thromboembolism (VTE) showed that, compared to Whites, Blacks had a significantly higher proportion with pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher proportion of Blacks with VTE were women (71% vs 61% for Whites) The study is published today in the American Journal of Hematology.

24 Jun 2010

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Merck (Merck is known as MSD outside the United States and Canada) today announced a strategic collaboration between MSD South Africa and Adcock Ingram, a publicly held South African company, to co-promote and distribute a number of established MSD products in South Africa. The products that will be jointly promoted by MSD and Adcock Ingram include over-the-counter (OTC) products and selected prescription medicines currently registered in South Africa by MSD and Schering-Plough.

24 Jun 2010

Stolen computers could jeopardize personal records of 1.2 million health plan members

American Medical News: "AvMed Health, a Florida-based health plan, said data about nearly 1.2 million members and former members were breached when two laptops were stolen in December 2009 from an AvMed office in Gainesville, Fla. The insurer notified 360,000 customers of the breach in February. But AvMed said on June 3 that further investigation found that an additional 860,000 people had been affected. Information included names, addresses, birth dates, Social Security numbers and health information.

24 Jun 2010

Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda

Affymax, Inc. today announced that it has received $30 million in development milestone payments from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™/peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.

22 Jun 2010

FDA to hold workshop on medical device innovation to address unmet public health needs

Each day, medical devices from renal dialysis machines to implantable defibrillators help prevent, diagnose, treat, and monitor serious and life-threatening diseases. After taking years to develop, these devices then undergo a regulatory review process before entering the marketplace. It then takes even more time for them to be adopted into clinical practice and for patients to realize the benefits.

22 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

Research roundup: Medical homes working in poor areas, designing insurance exchanges, health law's effects

Moving Forward On Health Reform - This edition explores the issues relating to the implementation of the Patient Protection and Affordable Care Act of 2010, including the impact of the law on health insurance as well as state and federal governments, large employers and public opinion and opportunities for small physician practices to pool resources in order support medical homes, among others (June 2010).

19 Jun 2010

Study: Patients in predominantly black areas less likely to receive kidney-related care

Regardless of race, fewer people see a kidney specialist before starting dialysis if they live in predominantly black communities, reports a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results highlight the importance of understanding why patients in predominantly black areas are less likely to receive kidney-related care while their kidney function is clearly declining.

18 Jun 2010

Implications for reducing clotting in kidney disease dialysis and sepsis

The interaction of the drug compstatin with two ancient, co-evolved human systems points to new ways for reducing clotting during dialysis for end-stage kidney disease and multiple organ failure due to sepsis, a dangerous whole-body inflammatory response to infection.

17 Jun 2010

UIC reports first successful robotic kidney transplant in morbidly obese patient

Surgeons at the University of Illinois at Chicago report the first successful robotic kidney transplant in a morbidly obese patient.

16 Jun 2010

Newly published research examines association between CKD and CYP24

Cytochroma today announced the publication of new data from studies in a preclinical model indicating that chronic kidney disease is associated with markedly increased expression of the vitamin D catabolic enzyme, CYP24, which contributes to vitamin D insufficiency and resistance to vitamin D therapy. Parallel analysis of kidney biopsies obtained from CKD patients confirmed abnormal CYP24 expression in human disease as well.

16 Jun 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

Central Washington Hospital improves patient experience with Toshiba' Vantage Titan MR system

In today's demanding health care environment, many community hospitals require imaging equipment that provides a variety of advanced diagnostic exams with features that improve patient cooperation. To offer a variety of high-quality, comfortable MR exams to its patients, Central Washington Hospital in Wenatchee, Wash., selected Toshiba America Medical Systems' Vantage TitanTM MR system.

15 Jun 2010

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Celgene International Sàrl announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival, the primary endpoint of the study.

14 Jun 2010

Dialysis News and Research

Latest Dialysis News and Research

Japan's MHLW grants full marketing authorization to REVLIMID

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

GI symptoms in peritoneal dialysis patients correlated with chronic renal failure

Digoxin drug may increase risk of premature death in patients with kidney disease

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Risk, incidence of VTE differs between races

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Stolen computers could jeopardize personal records of 1.2 million health plan members

Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda

FDA to hold workshop on medical device innovation to address unmet public health needs

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Research roundup: Medical homes working in poor areas, designing insurance exchanges, health law's effects

Study: Patients in predominantly black areas less likely to receive kidney-related care

Implications for reducing clotting in kidney disease dialysis and sepsis

UIC reports first successful robotic kidney transplant in morbidly obese patient

Newly published research examines association between CKD and CYP24

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Central Washington Hospital improves patient experience with Toshiba' Vantage Titan MR system

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Dialysis News and Research

Latest Dialysis News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in